首页> 外文OA文献 >Design and synthesis of high affinity ligands for the asialoglycoprotein receptor (ASGP-R)
【2h】

Design and synthesis of high affinity ligands for the asialoglycoprotein receptor (ASGP-R)

机译:设计和合成脱唾液酸糖蛋白受体(asGp-R)的高亲和力配体

摘要

The asialoglycoprotein receptor (ASGP-R) is a carbohydrate-binding protein fromudthe C-type lectin family that is expressed exclusively and in high numbers onudmammalian hepatocytes. The human ASGP-R is a transmembrane protein,udconsisting of two homologous subunits (H1 and H2), that recognizes and bindsuddesialylated glycoproteins with terminal galactose or N-acetylgalactosamineudresidues. The binding process is followed by receptor-mediated endocytosis ofudthe receptor-ligand complex by the parent hepatocyte. The ASGP-R is thenudrecycled back to the surface, whereas the ligand is ferried to the lysosomes forudenzymatic degradation. Due to its location and efficient ligand uptake, the ASGPRudhas for a long time been a validated target for liver-specific drug delivery.udFurthermore, there is substantial evidence that the ASGP-R is involved inudhepatitis B and C virus entry into the liver cells.udThe focus of this thesis was to design and synthesize various high affinity ligandsudfor the ASGP-R that could be used as (1) drug carriers for liver-specific druguddelivery, (2) small molecular weight inhibitors of hepatitis B/C entry, (3) a spinlabeledudGalNAc-based molecular probe for second binding site screening byudNMR, and (4) a set of trivalent compounds for investigating the localudconcentration effect on ligand affinity towards the ASGP-R by surface plasmonudresonance (BIACORE).udThe trivalent drug carrier for liver-specific drug delivery was shown to bind withudhigh affinity and selectivity to the ASGP-R, and is now awaiting the next step,udnamely, its conjugation to a therapeutic agent and in vivo testing.udThe TEMPO spin-labeled GalNAc derivative was successfully used as a first-siteudligand for second-site screening by NMR, in which imidazole was identified as audpotential second-site ligand. Therefore, after the removal of the TEMPO spinudlabel the first-site ligand will be used in further studies, involving “in situ click chemistry”, in order to find the appropriate linker for joining the first- and secondsiteudligands.udThe four trivalent compounds synthesized for investigating the localudconcentration effect had an identical molecular mass and scaffold, but differed inudthe ratio of D-galactose to D-glucose moieties per molecule. Since the affinity ofudglucose towards the ASGP-R is > 20 mM, and that of galactose is 2.2 mM, theudaffinity was expected to increase with increasing number of galactose moieties.udHowever, the compound bearing two galactose and one glucose residueudunexpectedly showed an affinity greater than that for a compound with threeudgalactose residues. The phenomenon is yet to be explained and verified byudfurther experiments. Nevertheless, the results presented in this work did confirmudthat the statistical local concentration effect has a weaker influence onudmultivalency than the chelate effect.
机译:去唾液酸糖蛋白受体(ASGP-R)是来自C型凝集素家族的碳水化合物结合蛋白,仅在U哺乳动物的肝细胞中大量表达。人ASGP-R是跨膜蛋白,由两个同源亚基(H1和H2)组成,可识别并与半乳糖或N-乙酰半乳糖胺/残基结合。结合过程之后,亲本肝细胞接受受体-配体复合物的受体介导的内吞作用。然后将ASGP-R再循环回表面,而将配体转移到溶酶体中进行脲酶降解。由于其位置和有效的配体摄取,ASGPR ud长期以来一直是肝特异性药物递送的有效靶标。 ud此外,有大量证据表明ASGP-R参与了乙型和丙型肝炎病毒的感染 ud本论文的重点是为ASGP-R设计和合成各种高亲和力配体 ud,可用作(1)肝特异性药物的药物载体 uddelivering,(2)小分子量乙型肝炎/乙型肝炎进入抑制剂,(3)旋转标记的基于 udGalNAc的分子探针,用于通过 udNMR进行第二次结合位点筛选,以及(4)一组三价化合物,用于研究配体对ASGP亲和力的局部/高浓度作用-ud通过表面等离振子/共振(BIACORE)。 ud显示用于肝特异性药物递送的三价药物载体与ASGP-R具有超高的亲和力和选择性结合,目前正在等待下一步, udp结合治疗剂和体内TEMPO自旋标记的GalNAc衍生物已成功用作NMR筛选第二位的第一位配位体,其中咪唑被鉴定为潜在的第二位配体。因此,在除去TEMPO自旋 udlabel之后,第一位配体将用于进一步的研究中,涉及“原位点击化学”,以便找到用于连接第一位和第二位 ud配体的合适接头。合成的用于研究局部/富集效应的四种三价化合物具有相同的分子量和骨架,但每个分子中D-半乳糖与D-葡萄糖部分的比率不同。由于葡糖对ASGP-R的亲和力> 20 mM,而半乳糖的亲和力为2.2 mM,因此 udaffinity预计会随着半乳糖部分数目的增加而增加。 ud然而,带有两个半乳糖和一个葡萄糖残基的化合物意外地显示出比具有三个半乳糖残基的化合物更高的亲和力。这种现象有待进一步的实验解释和验证。然而,这项工作中提出的结果确实证实了 udine统计局部浓度效应对螯合价的影响比螯合效应弱。

著录项

  • 作者

    Khorev Oleg;

  • 作者单位
  • 年度 2007
  • 总页数
  • 原文格式 PDF
  • 正文语种 {"code":"en","name":"English","id":9}
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号